肺部的放射剂量-体积效应。
Radiation dose-volume effects in the lung.
机构信息
Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA.
出版信息
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6. doi: 10.1016/j.ijrobp.2009.06.091.
Abstract
The three-dimensional dose, volume, and outcome data for lung are reviewed in detail. The rate of symptomatic pneumonitis is related to many dosimetric parameters, and there are no evident threshold "tolerance dose-volume" levels. There are strong volume and fractionation effects.
摘要
详细回顾了肺部的三维剂量、体积和结果数据。症状性放射性肺炎的发生率与许多剂量学参数有关，并且不存在明显的“耐受剂量-体积”阈值水平。存在强烈的体积和分割效应。
相似文献
1
Radiation dose-volume effects in the lung.肺部的放射剂量-体积效应。
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6. doi: 10.1016/j.ijrobp.2009.06.091.
2
Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?胸部立体定向体部放射治疗的危险器官考虑因素：肺实质的安全剂量是多少？
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):172-187. doi: 10.1016/j.ijrobp.2018.11.028. Epub 2018 Nov 26.
3
Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.在接受联合治疗的 IIIA-B 期 NSCLC 患者中，增加同侧 V20 和 V30 至常规剂量限制可预测放射性肺炎。
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):110-5. doi: 10.1016/j.ijrobp.2009.01.036.
4
A novel method to incorporate the spatial location of the lung dose distribution into predictive radiation pneumonitis modeling.将肺部剂量分布的空间位置纳入预测放射性肺炎建模的新方法。
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1549-55. doi: 10.1016/j.ijrobp.2011.05.007. Epub 2011 Jul 6.
5
Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis.使用剂量体积直方图分析在三维治疗计划中评估肺炎风险
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):455-60. doi: 10.1016/0360-3016(95)00009-N.
6
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.大系列立体定向体部放疗治疗肺部患者的放射性肺炎的临床和剂量学预测因素。
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5. doi: 10.1016/j.ijrobp.2012.03.041. Epub 2012 Aug 25.
7
Spatial Dose Patterns Associated With Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Photon Therapy With Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer.比较局部晚期非小细胞肺癌调强光子放疗与被动散射质子放疗的随机试验中与放射性肺炎相关的空间剂量分布。
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1124-1132. doi: 10.1016/j.ijrobp.2019.02.039. Epub 2019 Feb 26.
8
Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.剂量学因素与立体定向体部放射治疗中症状性放射性肺炎发展的相关性。
Radiat Oncol. 2020 Feb 13;15(1):33. doi: 10.1186/s13014-020-1479-6.
9
The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis.异质性校正对预测放射性肺炎的剂量学参数的影响。
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):125-31. doi: 10.1016/j.ijrobp.2005.09.047. Epub 2006 Jan 19.
10
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.利用临床、剂量学和空间参数对放射性肺炎风险进行建模。
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):112-24. doi: 10.1016/j.ijrobp.2005.11.046.
引用本文的文献
1
Induction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.诱导放化疗使局部晚期肺淋巴上皮瘤样癌实现长期无复发生存：一例报告及文献综述
Front Immunol. 2025 Jul 31;16:1605900. doi: 10.3389/fimmu.2025.1605900. eCollection 2025.
2
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.对于不可手术的III期非小细胞肺癌，在根治性放化疗后使用度伐鲁单抗巩固治疗对作为肺炎危险因素的治疗相关肺部浸润剂量效应关系的影响。
Transl Lung Cancer Res. 2025 Jun 30;14(6):2074-2088. doi: 10.21037/tlcr-2024-1284. Epub 2025 Jun 26.
3
Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review).晚期肝细胞癌中放射治疗与免疫检查点抑制剂的联合应用：当前证据与未来前景的系统评价（综述）
Oncol Lett. 2025 May 14;30(1):342. doi: 10.3892/ol.2025.15088. eCollection 2025 Jul.
4
Presence of Tissue Expanders Does Not Affect Radiotherapy Dose Distribution to Heart and Lungs.组织扩张器的存在不影响放疗对心脏和肺部的剂量分布。
Plast Reconstr Surg Glob Open. 2025 May 28;13(5):e6819. doi: 10.1097/GOX.0000000000006819. eCollection 2025 May.
5
Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in Curative Breast Cancer Patients Induced Pneumonitis: A Case Report.细胞周期蛋白依赖性激酶4/6抑制剂联合放疗致治愈性乳腺癌患者发生肺炎：一例报告
Life (Basel). 2025 Apr 27;15(5):709. doi: 10.3390/life15050709.
6
A Statistical Approach to Assess Biological Equivalent Mean Organ Dose (MOD) for Different Fractionations in Thoracic Radiotherapy.一种评估胸部放疗中不同分割方式下生物等效平均器官剂量（MOD）的统计方法。
Biomedicines. 2025 May 2;13(5):1110. doi: 10.3390/biomedicines13051110.
7
Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy.接受免疫治疗的肺癌患者预防放射性肺炎的最佳剂量-体积直方图阈值
Radiat Oncol. 2025 Apr 22;20(1):60. doi: 10.1186/s13014-025-02639-2.
8
Comprehensive clinical evaluation of novel 4DCT-based lung function imaging methods.基于新型4DCT的肺功能成像方法的综合临床评估。
J Appl Clin Med Phys. 2025 Jun;26(6):e70088. doi: 10.1002/acm2.70088. Epub 2025 Apr 8.
9
Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma.病例报告：一名肺腺癌患者在接受胸部放疗和达可替尼治疗后发生4级肺炎。
Front Oncol. 2025 Feb 25;15:1436134. doi: 10.3389/fonc.2025.1436134. eCollection 2025.
10
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT.非小细胞肺癌的治疗：PET-CT和IMRT/VMAT引入后的进展
Strahlenther Onkol. 2025 Mar 6. doi: 10.1007/s00066-025-02377-0.
本文引用的文献
1
A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.基于文献的放射性肺炎发生的临床危险因素的荟萃分析。
Acta Oncol. 2012 Nov;51(8):975-83. doi: 10.3109/0284186X.2012.718093. Epub 2012 Sep 5.
2
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.适用于不可切除非小细胞肺癌的调强放射治疗（IMRT）：纪念斯隆凯特琳癌症中心（MSKCC）的经验。
Radiother Oncol. 2008 Apr;87(1):17-23. doi: 10.1016/j.radonc.2008.02.005. Epub 2008 Mar 17.
3
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.用于切除性间皮瘤的调强放射治疗：杜克大学的经验。
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1143-50. doi: 10.1016/j.ijrobp.2007.11.011. Epub 2008 Feb 8.
4
Radiation-induced lung injury. Assessment, management, and prevention.放射性肺损伤。评估、管理与预防。
Oncology (Williston Park). 2008 Jan;22(1):37-47; discussion 52-3.
5
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data.一个用于预测放射性肺炎的列线图，源自对RTOG 9311和机构数据的综合分析。
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):985-92. doi: 10.1016/j.ijrobp.2007.04.077. Epub 2007 Aug 6.
6
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer.北美非小细胞肺癌立体定向体部放射治疗的经验。
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S101-12. doi: 10.1097/JTO.0b013e318074e4fa.
7
Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.肺部肿瘤立体定向放射治疗后出现症状性 2-5 级放射性肺炎的极高发生率。
Radiat Oncol. 2007 Jun 7;2:21. doi: 10.1186/1748-717X-2-21.
8
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.恶性胸膜间皮瘤术后调强放疗后的剂量依赖性肺毒性。
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7. doi: 10.1016/j.ijrobp.2007.03.011. Epub 2007 Apr 30.
9
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.同步化疗联合调强放疗治疗晚期非小细胞肺癌患者时治疗相关性肺炎的初步评估
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):94-102. doi: 10.1016/j.ijrobp.2006.12.031. Epub 2007 Feb 22.
10
Updated assessment of the six-minute walk test as predictor of acute radiation-induced pneumonitis.作为急性放射性肺炎预测指标的六分钟步行试验的最新评估
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):759-67. doi: 10.1016/j.ijrobp.2006.10.001.
Zotero 插件